Patent classifications
A61L24/108
ONE COMPONENT FIBRIN GLUE COMPRISING A POLYMERIZATION INHIBITOR
Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations.
HYDROGELS AND USE THEREOF IN ANASTOMOSIS PROCEDURES
This disclosure provides novel hydrogels that can undergo multiple gel-sol transitions and methods of making and using such hydrogels, particularly in anastomosis procedures. The peptide hydrogels comprising a fibrillar network of peptides that are in an amphiphilic β-hairpin conformation. The peptides comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel. Isolated peptides for making the disclosed hydrogels are provided, as are methods of using the peptide hydrogels in anastomosis procedures.
Collagen gel formulations
The present inventors have developed printable collagen bioinks using unmodified type I collagen with mechanical and structural properties that facilitate application to tissue in a structured form. In particular, the compositions of the present invention may be used to apply collagen gels to tissue (e.g. eye) using two- or three-dimensional (extrusion) bioprinting techniques.
COMPOSITIONS AND METHODS FOR USING SILK-ELASTINLIKE PROTEIN-BASED POLYMERS
Disclosed are methods of treating an aneurysm in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a SELP. Disclosed are methods of preventing rupture of an aneurysm comprising administering to a subject having an aneurysm a composition comprising a SELP, wherein the SELP is present in the aneurysm and prevents rupture. Also disclosed are methods of embolizing an aneurysm in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising SEEP. Disclosed are methods of treating AVM in a subject comprising administering to the subject a composition comprising a SELP. In some aspects, the SELP embolizes an abnormal blood vessel in the AVM. Disclosed are methods of embolizing an AVM in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising a SELP, wherein the SELP embolizes an abnormal blood vessel in the AVM.
Tissue adhesive for use in a treatment method in which an ophthalmological implant is implanted in a human or animal patient, and ophthalmological implantation system
The disclosure relates to a tissue adhesive for use in a treatment method in which an ophthalmological implant is implanted in a human or animal patient and the ophthalmological implant is connected, at least partially in an integrally bonded manner, to eye tissue of the patient via the tissue adhesive. The disclosure also relates to an ophthalmological implantation system including an ophthalmological implant for implantation in a human or animal eye and to a tissue adhesive via which the ophthalmological implant is connectable, at least partially in an integrally bonded manner, to eye tissue of the patient.
FIBRINOGEN AND THROMBIN SOLUTIONS FOR A FIBRIN SEALANT AND FIBRIN SEALANT KIT
Disclosed are a fibrinogen solution and a thrombin solution. The fibrinogen solution comprises fibrinogen at a concentration of at least 40 mg/ml, factor XIII, pharmaceutically acceptable additives and water. The dynamic viscosity of the fibrinogen solution measured at 20° C. increases at most by 35% after storing the solution at 20° C. for 30 days. The thrombin solution comprises thrombin, pharmaceutically acceptable additives and water. The thrombin activity decreases at most by 15% after storing the solution at 25° C. for 14 days. Also disclosed is a fibrin sealant kit with a first container comprising the fibrinogen solution and a second container comprising the thrombin solution. Further, methods for preparing a fibrin sealant and methods for treating a wound are disclosed.
BRONCHIAL EMBOLIZATION MATERIAL
A material for endobronchial occlusion capable of repairing or replacing tissue is disclosed. The material contains a protein (A), wherein the protein (A) contains at least one of a polypeptide chain (Y) or a polypeptide chain (Y′), a total number of the polypeptide chain (Y) and the polypeptide chain (Y′) in the protein (A) is 1 to 100, the polypeptide chain (Y) is a polypeptide chain consisting of 2 to 200 tandem repeats of at least one amino acid sequence (X) among an amino acid sequence VPGVG, an amino acid sequence GVGVP 4, GPP, GAP, and an amino acid sequence GAHGPAGPK, the polypeptide chain (Y′) is a polypeptide chain in which each of a total of 5% or less of amino acids in the polypeptide chain (Y) is replaced by at least one of a lysine residue or an arginine residue, with a total number of the lysine and arginine residues being 1 to 100.
METHODS AND COMPOSITIONS FOR MENISCAL REPAIR USING BIOADHESIVE PROTEINS
Compositions and methods are directed to engineered extracellular matrix protein—mussel foot protein fusions for use as a bioadhesive for repairing tissues. The compositions have one or more of: (i) at least one hydrophobic region; (ii) at least one crosslinking region; (iii) at least one tyrosine residue accessible to be enzymatically modified to a DOPA or TOPA side chain; (iv) at least one mussel foot protein; (v) at least one mussel foot protein loop; (vi) at least one human extracellular protein loop; or (vii) at least one of the following sequences: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6. The elastin-like polypeptide includes at least one non-naturally occurring amino acid or sequence alteration.
Biocompatible phase invertible proteinaceous compositions and methods for making and using the same
Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.
Spray-dried thrombin and methods of using and making spray-dried thrombin
Spray-dried thrombin materials obtained from feedstock solutions comprising less than 5% by weight albumin and excluding trehalose or other excipients as well as methods of manufacturing the thrombin materials and methods of treating bleeding wounds are disclosed. The methods of use include applying reconstituted spray-dried thrombin topically to a bleeding site, optionally in conjunction with gelatin.